CeriBell (NASDAQ:CBLL) VP David Foehr Sells 993 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 993 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $24.02, for a total transaction of $23,851.86. Following the completion of the transaction, the vice president owned 36,758 shares of the company’s stock, valued at $882,927.16. This trade represents a 2.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David Foehr also recently made the following trade(s):

• On Monday, August 24th, David Foehr sold 859 shares of CeriBell stock. The stock was sold at an average price of $23.95, for a total value of $20,573.05.

CeriBell Stock Performance

CBLL opened at $23.95 on Wednesday. The business has a 50 day moving average price of $19.77 and a two-hundred day moving average price of $19.27. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. The company has a market capitalization of $919.20 million, a price-to-earnings ratio of -13.61 and a beta of 0.81. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $25.33.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. The firm had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. Research analysts predict that CeriBell, Inc. will post -1.96 EPS for the current fiscal year.

Institutional Investors Weigh In On CeriBell

Several institutional investors and hedge funds have recently modified their holdings of CBLL. BlackRock Inc. acquired a new position in shares of CeriBell during the 2nd quarter valued at about $37,657,000. Vanguard Group Inc. increased its holdings in shares of CeriBell by 11.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after purchasing an additional 147,013 shares during the period. KCM Capital Inc lifted its position in shares of CeriBell by 40.0% in the 1st quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock worth $25,662,000 after acquiring an additional 400,000 shares during the period. Yu Fan raised its stake in shares of CeriBell by 10.7% in the second quarter. Yu Fan now owns 1,353,166 shares of the company’s stock valued at $25,345,000 after purchasing an additional 130,964 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in CeriBell by 1,945.9% in the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after purchasing an additional 1,162,200 shares during the period.

More CeriBell News

Here are the key news stories impacting CeriBell this week:

• Neutral Sentiment: CEO Xingjuan Chao, CFO Scott Blumberg, CTO Raymond Woo, CRO Joseph S. Manni and VP David Foehr collectively sold approximately 12,781 shares for about $307,000. Each filing stated that the shares were sold to cover tax-withholding obligations after equity awards vested, and the executives retained substantial remaining holdings. SEC insider transaction filings
• Neutral Sentiment: Reported short interest was zero shares as of August 25, unchanged from zero shares on August 10, with a zero-day days-to-cover ratio. Because the figures include a “NaN” change and may reflect incomplete or anomalous reporting, they provide little actionable information about bearish positioning.
• Negative Sentiment: The cluster of sales by multiple senior executives could create a modest overhang for CBLL, particularly with the stock trading close to its 12-month peak. However, the relatively small size of the transactions and their stated tax-related purpose lessen the signal that management is broadly reducing exposure.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on CBLL shares. Barclays raised shares of CeriBell to a “neutral” rating in a report on Tuesday, August 18th. Canaccord Genuity Group boosted their target price on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Finally, BTIG Research lifted their price target on shares of CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, CeriBell currently has an average rating of “Moderate Buy” and a consensus price target of $22.40.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.